Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.84 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.83 |
| ▸ | NPY1R | P25929 | 1/20 | 0.83 |
| ▸ | NPY2R | P49146 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL23668766 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL2406939 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL40916 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL14744146 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL40917 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.93 | ADRB2 (0.88) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL3123840 | 0.93 | ADRB2 (0.88) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL1561123 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| (R)-Metoprolol SCHEMBL40918 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL4093 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260047897-A1 | TECHNICAL AND THEORETICAL SPECIFICATIONS FOR SMALL-SCALE MACHINES AND MICRO-ROBOTS FOR DESTROYING ANY HARMFUL MATTER INSIDE A LIVING ORGANISM USING A SUPERCRITICAL FLUID | HOFFMAN JASON (US) | 2026-02-19 | — | — | US | claimed |
| EP-4482373-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC MANAGEMENT OF HEART FAILURE PATIENTS | Cedars-Sinai Medical Center (US) | 2025-01-01 | — | — | EP | claimed |
| CN-118787605-A | Metoprolol succinate sustained-release pellets and capsules and preparation method thereof | 上海惠永药物研究有限公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | claimed |
| CN-118286182-A | Metoprolol succinate microcapsule and preparation method thereof | 杭州沐源生物医药科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC | 2024-05-09 | — | — | US | claimed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | claimed |
| US-20240122859-A1 | EXTENDED RELEASE MULTIPLE UNIT PELLET SYSTEM COMPOSITION AND ITS PROCESS FOR THE PREPARATION | NOKHA TRADING LLP (IN) | 2024-04-18 | — | — | US | claimed |
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| WO-2007047371-A2 | PHARMACEUTICAL PACKAGING OF AN ORAL DOSAGE COMBINATION | MICRODOSE TECHNOLOGIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20070087048-A1 | Oral dosage combination pharmaceutical packaging | MICRODOSE THERAPEUTX, INC. | 2007-04-19 | — | — | US | claimed |
| WO-2007036952-A2 | NOVEL SUSTAINED RELEASE DOSAGE FORM | RUBICON RESEARCH PVT LTD. (IN) | 2007-04-05 | — | — | WO | claimed |
| EP-1599190-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2005-11-30 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| EP-0293347-B1 | METOPROLOL SUCCINATE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | Aktiebolaget Hässle (SE) | 1992-06-10 | — | — | EP | claimed |
| US-5081154-A | METOPROLOL SUCCINATE | AKTIEBOLAGET HASSLE (SE) | 1992-01-14 | — | — | US | claimed |
| EP-0293347-A1 | Metoprolol succinate and pharmaceutical composition containing it | Aktiebolaget Hässle (SE) | 1988-11-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047897-A1 | TECHNICAL AND THEORETICAL SPECIFICATIONS FOR SMALL-SCALE MACHINES AND MICRO-ROBOTS FOR DESTROYING ANY HARMFUL MATTER INSIDE A LIVING ORGANISM USING A SUPERCRITICAL FLUID | MYLK, MYLK2, MYC | ADRB1 357/4885ADRB2 311/4885ADRA1A 943/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ADRB1 309/4885ADRB2 246/4885ADRA1A 687/4885 |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | CNR2, CNR1, FAAH | ADRB1 717/4885ADRB2 576/4885ADRA1A 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.